These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies. Ugale V; Dhote A; Narwade R; Khadse S; Reddy PN; Shirkhedkar A CNS Neurol Disord Drug Targets; 2021; 20(9):822-862. PubMed ID: 33687902 [TBL] [Abstract][Full Text] [Related]
3. GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases. Ladagu AD; Olopade FE; Adejare A; Olopade JO Pharmaceuticals (Basel); 2023 Oct; 16(11):. PubMed ID: 38004401 [TBL] [Abstract][Full Text] [Related]
4. GluN2B-containing NMDARs in the mammalian brain: pharmacology, physiology, and pathology. Ge Y; Wang YT Front Mol Neurosci; 2023; 16():1190324. PubMed ID: 37324591 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([ Fu H; Tang W; Chen Z; Belov VV; Zhang G; Shao T; Zhang X; Yu Q; Rong J; Deng X; Han W; Myers SJ; Giffenig P; Wang L; Josephson L; Shao Y; Davenport AT; Daunais JB; Papisov M; Yuan H; Li Z; Traynelis SF; Liang SH ACS Chem Neurosci; 2019 May; 10(5):2263-2275. PubMed ID: 30698943 [TBL] [Abstract][Full Text] [Related]
6. A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists. Stroebel D; Buhl DL; Knafels JD; Chanda PK; Green M; Sciabola S; Mony L; Paoletti P; Pandit J Mol Pharmacol; 2016 May; 89(5):541-51. PubMed ID: 26912815 [TBL] [Abstract][Full Text] [Related]
8. A Rare Variant Identified Within the GluN2B C-Terminus in a Patient with Autism Affects NMDA Receptor Surface Expression and Spine Density. Liu S; Zhou L; Yuan H; Vieira M; Sanz-Clemente A; Badger JD; Lu W; Traynelis SF; Roche KW J Neurosci; 2017 Apr; 37(15):4093-4102. PubMed ID: 28283559 [TBL] [Abstract][Full Text] [Related]
9. Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold. Ritter N; Korff M; Markus A; Schepmann D; Seebohm G; Schreiber JA; Wünsch B Cell Physiol Biochem; 2021 Mar; 55(S3):1-13. PubMed ID: 33656308 [TBL] [Abstract][Full Text] [Related]
10. Altered GluN2B NMDA receptor function and synaptic plasticity during early pathology in the PS2APP mouse model of Alzheimer's disease. Hanson JE; Pare JF; Deng L; Smith Y; Zhou Q Neurobiol Dis; 2015 Feb; 74():254-62. PubMed ID: 25484285 [TBL] [Abstract][Full Text] [Related]
11. The chemical biology of clinically tolerated NMDA receptor antagonists. Chen HS; Lipton SA J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of Tyrosine 1070 at the GluN2B Subunit Is Regulated by Synaptic Activity and Critical for Surface Expression of N-Methyl-D-aspartate (NMDA) Receptors. Lu W; Fang W; Li J; Zhang B; Yang Q; Yan X; Peng L; Ai H; Wang JJ; Liu X; Luo J; Yang W J Biol Chem; 2015 Sep; 290(38):22945-54. PubMed ID: 26229100 [TBL] [Abstract][Full Text] [Related]
14. Dopamine depletion of the striatum causes a cell-type specific reorganization of GluN2B- and GluN2D-containing NMDA receptors. Zhang X; Chergui K Neuropharmacology; 2015 May; 92():108-15. PubMed ID: 25619731 [TBL] [Abstract][Full Text] [Related]